ICU Medical, Inc. (NASDAQ:ICUI) Short Interest Down 10.1% in September

ICU Medical, Inc. (NASDAQ:ICUI) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 831,100 shares, a drop of 10.1% from the August 31st total of 924,500 shares. Based on an average daily volume of 337,000 shares, the short-interest ratio is currently 2.5 days. Currently, 3.7% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ICUI. Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Thursday, August 8th. KeyCorp lifted their target price on ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Finally, StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and a consensus target price of $149.00.

ICU Medical Price Performance

ICU Medical stock opened at $182.22 on Tuesday. The firm has a market cap of $4.44 billion, a PE ratio of -74.38 and a beta of 0.65. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. The stock’s fifty day moving average price is $155.95 and its two-hundred day moving average price is $124.76. ICU Medical has a one year low of $78.28 and a one year high of $188.53.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter last year, the business earned $1.58 earnings per share. ICU Medical’s revenue was up 8.6% on a year-over-year basis. As a group, research analysts expect that ICU Medical will post 3.76 EPS for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at $17,096,771.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,552 shares of company stock worth $4,537,802. Company insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Large investors have recently made changes to their positions in the company. Motco bought a new stake in ICU Medical during the first quarter worth $29,000. Innealta Capital LLC bought a new stake in shares of ICU Medical during the 2nd quarter worth $32,000. GAMMA Investing LLC lifted its position in shares of ICU Medical by 75.1% during the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 133 shares during the last quarter. EntryPoint Capital LLC boosted its stake in ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 395 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in ICU Medical by 46.4% in the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.